Researchers develop promising new cancer vaccine

(If you're not yet a fan, join us now by clicking the Like button)

Scientists report on the design of an anticancer vaccine targeting MUC1, which triggers strong humoral and cellular immune responses in vivo, and leads to a significant reduction in tumor burden in animals carrying MUC1-expressing tumors. Sandra Gendler, Ph.D., at Mayo Clinic in Arizona, explains how researchers at Mayo Clinic and the University of Georgia (UGA) have developed this vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases — including those that are resistant to common treatments

PNAS & Mayoclinic

Comments are closed.